ES2177022T3 - Un itraconazol que exhibe una solubilidad mejorada, un metodo para preparar el mismo y una composicion farmaceutica para administracion oral que comprende el mismo. - Google Patents

Un itraconazol que exhibe una solubilidad mejorada, un metodo para preparar el mismo y una composicion farmaceutica para administracion oral que comprende el mismo.

Info

Publication number
ES2177022T3
ES2177022T3 ES98929878T ES98929878T ES2177022T3 ES 2177022 T3 ES2177022 T3 ES 2177022T3 ES 98929878 T ES98929878 T ES 98929878T ES 98929878 T ES98929878 T ES 98929878T ES 2177022 T3 ES2177022 T3 ES 2177022T3
Authority
ES
Spain
Prior art keywords
same
exhibits
itraconazol
understands
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98929878T
Other languages
English (en)
Inventor
Bong-Jin Cha
Jun-Gyo Oh
Su-Eon Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong A Pharmaceutical Co Ltd
Original Assignee
Dong A Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharmaceutical Co Ltd filed Critical Dong A Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2177022T3 publication Critical patent/ES2177022T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un itraconazol que exhibe una disponibilidad mejorada, en donde el diámetro de las partículas de itraconazol está en el intervalo de 0,5 a 10 µm y el itraconazol tiene una forma amorfa.
ES98929878T 1997-06-16 1998-06-16 Un itraconazol que exhibe una solubilidad mejorada, un metodo para preparar el mismo y una composicion farmaceutica para administracion oral que comprende el mismo. Expired - Lifetime ES2177022T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019970024938A KR19990001564A (ko) 1997-06-16 1997-06-16 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제

Publications (1)

Publication Number Publication Date
ES2177022T3 true ES2177022T3 (es) 2002-12-01

Family

ID=19509733

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98929878T Expired - Lifetime ES2177022T3 (es) 1997-06-16 1998-06-16 Un itraconazol que exhibe una solubilidad mejorada, un metodo para preparar el mismo y una composicion farmaceutica para administracion oral que comprende el mismo.

Country Status (17)

Country Link
US (1) US6346533B1 (es)
EP (1) EP0991646B1 (es)
JP (1) JP2002504930A (es)
KR (1) KR19990001564A (es)
CN (1) CN1129598C (es)
AT (1) ATE216699T1 (es)
AU (1) AU7939298A (es)
BR (1) BR9810124A (es)
CA (1) CA2294398A1 (es)
DE (1) DE69805070T2 (es)
DK (1) DK0991646T3 (es)
ES (1) ES2177022T3 (es)
HU (1) HUP0004050A3 (es)
PL (1) PL338631A1 (es)
PT (1) PT991646E (es)
WO (1) WO1998057967A1 (es)
YU (1) YU66799A (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60023465T2 (de) 1999-03-24 2006-07-20 R.P. Scherer Technologies, Inc., Las Vegas Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
IT1312115B1 (it) * 1999-06-24 2002-04-04 Nicox Sa Composti amorfi e relative composizioni farmaceutiche
KR100694667B1 (ko) * 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
KR20010097244A (ko) * 2000-04-21 2001-11-08 유충식 위산도 비의존성 고용해도를 갖는 이트라코나졸 함유약학적 조성물 및 그 제조방법
KR100432949B1 (ko) * 2000-06-13 2004-05-31 코오롱제약주식회사 생체이용율이 향상된 이트라코나졸의 분립체 조성물과이를 이용한 이트라코나졸 제제 및 그 제조방법
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
BR0116377A (pt) * 2000-12-22 2005-12-13 Baxter Int Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20040173147A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US6962715B2 (en) * 2001-10-24 2005-11-08 Hewlett-Packard Development Company, L.P. Method and dosage form for dispensing a bioactive substance
US20040173146A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
AU2002317063A (en) * 2001-06-12 2002-12-23 Smartrix Technologies Inc Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
US7163700B2 (en) 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
CA2480377A1 (en) * 2002-03-26 2003-10-09 Teva Pharmaceutical Industries Ltd. Drug microparticles
AU2003243354A1 (en) 2002-05-31 2003-12-19 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
MXPA05000232A (es) 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
KR100557680B1 (ko) * 2002-11-23 2006-03-07 한국유나이티드제약 주식회사 이트라코나졸의 용해도 개선을 위한 펠렛제제 및 그제조방법
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
DK1438960T4 (da) * 2003-01-14 2013-03-25 Cimex Pharma Ag Sammensætning af itraconazol dispergeret i en hydrofil polymer med forhøjet biotilgængelighed
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
CN1905905B (zh) * 2003-09-22 2011-06-08 巴克斯特国际公司 用于药物制剂和医药产品最终灭菌的高压灭菌
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
WO2005082915A1 (en) * 2004-02-26 2005-09-09 Zentiva, A.S. Amorphous forms of risedronate monosodium
CN1294912C (zh) * 2004-03-01 2007-01-17 上海医药工业研究院 伊曲康唑盐酸盐组合物及其冻干粉针
US20050202051A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical vehicle
US20050203482A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical dispensing apparatus and method
CA2598204C (en) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
US20060182777A1 (en) * 2005-02-15 2006-08-17 Steve Kangas Method of modulating drug release from a coated substrate
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
GB0818403D0 (en) * 2008-10-08 2008-11-12 Univ Leuven Kath Aqueous electrophoretic deposition
WO2010040648A2 (en) * 2008-10-06 2010-04-15 Katholieke Universiteit Leuven, K.U.Leuven R&D Functional layers of biomolecules and living cells, and a novel system to produce such
CN104224687A (zh) * 2014-09-28 2014-12-24 武汉药谷生物工程有限公司 硝酸异康唑阴道栓及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368200A (en) 1978-06-23 1983-01-11 Janssen Pharmaceutica N.V. Heterocyclic derivatives of (4-phenyl-piperazine-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4490530A (en) 1981-01-14 1984-12-25 Janssen Pharmaceutica N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles
JPS60139688A (ja) * 1983-12-28 1985-07-24 Tokyo Tanabe Co Ltd 無定形ジヒドロピリジン粉末製剤
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4870060A (en) 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
WO1994016700A1 (en) * 1993-01-27 1994-08-04 Sepracor, Inc. Method and composition employing (2r,4s) itraconazole
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
EP0862463A1 (en) * 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
US5686133A (en) * 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
EE03902B1 (et) * 1996-05-20 2002-12-16 Janssen Pharmaceutica N.V. Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend

Also Published As

Publication number Publication date
DK0991646T3 (da) 2002-06-10
HUP0004050A3 (en) 2003-03-28
KR19990001564A (ko) 1999-01-15
PL338631A1 (en) 2000-11-06
JP2002504930A (ja) 2002-02-12
BR9810124A (pt) 2000-08-08
DE69805070T2 (de) 2002-11-07
CN1262682A (zh) 2000-08-09
ATE216699T1 (de) 2002-05-15
PT991646E (pt) 2002-08-30
WO1998057967A1 (en) 1998-12-23
HUP0004050A2 (hu) 2001-06-28
CA2294398A1 (en) 1998-12-23
US6346533B1 (en) 2002-02-12
EP0991646B1 (en) 2002-04-24
EP0991646A1 (en) 2000-04-12
AU7939298A (en) 1999-01-04
DE69805070D1 (de) 2002-05-29
CN1129598C (zh) 2003-12-03
YU66799A (sh) 2002-06-19

Similar Documents

Publication Publication Date Title
ES2177022T3 (es) Un itraconazol que exhibe una solubilidad mejorada, un metodo para preparar el mismo y una composicion farmaceutica para administracion oral que comprende el mismo.
BR9610988A (pt) Composto uso do mesmo fomulação farmacêutica e processo para produção do composto
ES2116447T3 (es) Una composicion farmaceutica que contiene un sistema definido de lipidos.
MX9405219A (es) Nueva formulacion farmaceutica.
AR017079A1 (es) Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso.
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
CO4560547A1 (es) Una forma de dosis de azitromicina y un metodo de trata- miento de una infeccion microbiana que involucra la adminis- tracion de azitromicina
DE60100186D1 (de) Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
ATE259805T1 (de) Als arzneimittel einsetzbare anticholinergika sowie verfahren zu deren herstellung
NO961742D0 (no) Anvendelse av retinoider i et kosmetisk preparat eller for fremstilling av et farmsöytisk preparat
BR1100507A (pt) Processo para melhorar o desempenho de dissolução de um composto farmacêutico em uma forma de dosagem sólida.
FR2705566B1 (fr) Nouvelles compositions pharmaceutiques.
AR064901A2 (es) Una pelicula consumible adaptada para disolverse en la boca de un consumidor
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
IT1243357B (it) Metodo per preparare una composizione farmaceutica in forma di microparticelle
BR9713215A (pt) Formulação de partìcula revestida
AR059764A2 (es) Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene
RS49602B (sr) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
BR9809571A (pt) Composição medicinal e processo para produzì-la
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
BR9602025A (pt) Composto composição farmacêutica uso e processo para a preparação de um composto
AR036444A1 (es) Material de pelicula
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.